Related references
Note: Only part of the references are listed.Internalization pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles
Wael Rima et al.
BIOMATERIALS (2013)
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
Emilia Mahoney et al.
BLOOD (2012)
CD38 and chronic lymphocytic leukemia: a decade later
Fabio Malavasi et al.
BLOOD (2011)
Lysosomal Transmembrane Protein LAPTM4B Promotes Autophagy and Tolerance to Metabolic Stress in Cancer Cells
Yang Li et al.
CANCER RESEARCH (2011)
Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
Giorgio Zauli et al.
CLINICAL CANCER RESEARCH (2011)
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Ravi K. Amaravadi et al.
CLINICAL CANCER RESEARCH (2011)
The molecular background of aggressive B cell lymphomas as a basis for targeted therapy
Daphne de Jong et al.
JOURNAL OF PATHOLOGY (2011)
Nanomaterials for cancer therapy and imaging
Ki Hyun Bae et al.
MOLECULES AND CELLS (2011)
Nanoparticle-induced vascular blockade in human prostate cancer
Lilach Agemy et al.
BLOOD (2010)
The Lysosomotropic Agent, Hydroxychloroquine, Delivered in a Biodegradable Nanoparticle System, Overcomes Drug Resistance of B-Chronic Lymphocytic Leukemia Cells In Vitro
Eduardo Mansilla et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Vladimir Krystof et al.
CURRENT DRUG TARGETS (2010)
Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8
A. Bicho et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Targeting of drugs and nanoparticles to tumors
Erkki Ruoslahti et al.
JOURNAL OF CELL BIOLOGY (2010)
Biodegradable PLGA Based Nanoparticles for Sustained Regional Lymphatic Drug Delivery
Deepa A. Rao et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Interaction of the Retinoblastoma Protein with Orc1 and Its Recruitment to Human Origins of DNA Replication
Ramiro Mendoza-Maldonado et al.
PLOS ONE (2010)
Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma
Gustavo H. Marin et al.
CURRENT CLINICAL PHARMACOLOGY (2010)
Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells
Rayhana Rahim et al.
ANTI-CANCER DRUGS (2009)
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
Sarbari Acharya et al.
BIOMATERIALS (2009)
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Nathalie A. Johnson et al.
BLOOD (2009)
Nanoparticles of Biodegradable Polymers for Cancer Treatment
BIOMATERIALS (2008)
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M. Mead et al.
BLOOD (2008)
Polymeric nanoparticles for cancer therapy
Suphiya Parveen et al.
JOURNAL OF DRUG TARGETING (2008)
Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications
Federica Chiellini et al.
NANOMEDICINE (2008)
Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles
Ayush Verma et al.
NATURE MATERIALS (2008)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Ocular Toxicity of Hydroxychloroquine
Rodney Tehrani et al.
Seminars in Ophthalmology (2008)
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al.
NATURE NANOTECHNOLOGY (2007)
Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas
Luis Fayad et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Autophagosome formation: Core machinery and adaptations
Zhiping Xie et al.
NATURE CELL BIOLOGY (2007)
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy
Eric M. Pridgen et al.
NANOMEDICINE (2007)
Biodegradable nanoparticles for cytosolic delivery of therapeutics
Jaspreet K. Vasir et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Pathways of clathrin-independent endocytosis
Satyajit Mayor et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Complement as effector system in cancer immunotherapy
Paolo Macor et al.
IMMUNOLOGY LETTERS (2007)
New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?
Si-Shen Feng
NANOMEDICINE (2006)
Monoclonal antibody therapy of chronic lymphocytic leukemia
BD Cheson
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59
F Ziller et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents
Y Zhou et al.
BLOOD (2003)
The dawning era of polymer therapeutics
R Duncan
NATURE REVIEWS DRUG DISCOVERY (2003)
Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of bcl-2/bax/ratio
L Lagneaux et al.
LEUKEMIA & LYMPHOMA (2002)
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
B Bellosillo et al.
BLOOD (2001)
Management of chronic lymphocytic leukaemia
N Kalil et al.
DRUGS & AGING (2000)
Share Paper
